<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Whether free fatty acid (FFA) rate of appearance (R(a)) is increased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is controversial </plain></SENT>
<SENT sid="1" pm="."><plain>To characterize nocturnal and postprandial abnormalities in FFA kinetics and to determine the effects of treatment with <z:chebi fb="0" ids="50864">insulin sensitizers</z:chebi> on lipolysis, we measured <z:chebi fb="2" ids="29889">palmitate</z:chebi> R(a) in control subjects (n = 6) and individuals with poorly controlled, <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>-treated type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (HbA(1c) = 8.7 +/- 0.2%, n = 20), the latter before and at the end of 12 weeks of treatment with <z:chebi fb="0" ids="9753">troglitazone</z:chebi> (600 mg/day, n = 4), <z:chebi fb="0" ids="6801">metformin</z:chebi> ( approximately 2,000 mg/day, n = 8), or placebo (n = 8) </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects consumed a standard breakfast at 0800 h </plain></SENT>
<SENT sid="3" pm="."><plain>Results in control subjects and type 2 diabetic subjects were compared at baseline </plain></SENT>
<SENT sid="4" pm="."><plain>Integrated nocturnal FFA R(a) (AUC(1:00-8:00 A.M.)) was approximately 50% higher in type 2 diabetic subjects than in control subjects (29.4 +/- 3.0 vs. 19.4 +/- 3.9 mmol </plain></SENT>
<SENT sid="5" pm="."><plain>m(-2) </plain></SENT>
<SENT sid="6" pm="."><plain>7 h(-1), respectively, P &lt; 0.05), whereas postprandial <z:chebi fb="2" ids="29889">palmitate</z:chebi> R(a) (AUC(0-240 min)) was almost threefold higher in type 2 diabetic subjects than in control subjects (14.2 +/- 1.7 vs. 5.3 +/- 1.0 mmol </plain></SENT>
<SENT sid="7" pm="."><plain>m(-2) </plain></SENT>
<SENT sid="8" pm="."><plain>4 h(-1), respectively, P &lt; 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>After <z:chebi fb="0" ids="9753">troglitazone</z:chebi> treatment, nocturnal <z:chebi fb="2" ids="29889">palmitate</z:chebi> R(a) did not change, but postprandial <z:chebi fb="2" ids="29889">palmitate</z:chebi> R(a) decreased by approximately 30% (P &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="2" ids="29889">Palmitate</z:chebi> kinetics did not change with <z:chebi fb="0" ids="6801">metformin</z:chebi> or placebo treatment </plain></SENT>
<SENT sid="11" pm="."><plain>In summary, nocturnal and postprandial FFA R(a) is increased in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>Postprandial lipolysis appears to be preferentially improved by <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> compared with nocturnal lipolysis </plain></SENT>
</text></document>